ProBioGen, LAVA Therapeutics close second cell line development agreement
ProBioGen and LAVA Therpuetics N.V. have closed a second cell line development agreement to support a bispecific gamma-delta T cell engager (TCE) candidate in LAVA’s pipeline. Under the agreement and using its CHO.RiGHT expression platform, including its DirectedLuck Transposase technology for the generation of stable high-titer cell lines, ProBioGen will conduct cell line development of a novel […]
